PNC-27 10ml

Quickstart Highlights

PNC-27 is a synthetic 32‑amino‑acid peptide containing an HDM‑2‑binding domain linked to a membrane‑penetrating sequence, studied preclinically for its selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 complexes[1][2]. No human clinical trials exist, and the FDA explicitly warns that PNC-27 products are unapproved and lack established safety data[3]. This educational protocol presents a once‑daily subcutaneous approach using a practical dilution for clear insulin‑syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → 10 mg/mL concentration.
Typical daily range: 100–500 mcg once daily (gradual titration).
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 100 mcg on a U‑100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = 10 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	100 mcg (0.10 mg)	1 unit (0.01 mL)
Weeks 3–4	200 mcg (0.20 mg)	2 units (0.02 mL)
Weeks 5–8	300 mcg (0.30 mg)	3 units (0.03 mL)
Weeks 9–12	400 mcg (0.40 mg)	4 units (0.04 mL)
Weeks 13–16	500 mcg (0.50 mg)	5 units (0.05 mL)

Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Critical Note: No authoritative human dosing exists for PNC-27. The FDA warns that PNC-27 safety has not been established[3]. Any dosing above a few hundred micrograms per day is purely speculative[4].

Reconstitution Steps

Reference-derived details for PNC-27 10ml.

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Supplies Needed

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (PNC-27, 30 mg each):
Peptide Vials (PNC-27, 30 mg each):: 8 weeks ≈ 1 vial (~15–20 mg total used)
Peptide Vials (PNC-27, 30 mg each):: 12 weeks ≈ 1 vial (~25 mg total used)
Peptide Vials (PNC-27, 30 mg each):: 16 weeks ≈ 2 vials (~35–40 mg total used)
Insulin Syringes (U‑100 or 30/50‑unit for precision):
Insulin Syringes (U‑100 or 30/50‑unit for precision):: Per week: 7 syringes (1/day)
Insulin Syringes (U‑100 or 30/50‑unit for precision):: 8 weeks: 56 syringes
Insulin Syringes (U‑100 or 30/50‑unit for precision):: 12 weeks: 84 syringes
Insulin Syringes (U‑100 or 30/50‑unit for precision):: 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 12 weeks (1 vial): 3 mL → 1 × 10 mL bottle
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.: 16 weeks (2 vials): 6 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: Per week: 14 swabs (2/day)
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
Alcohol Swabs: One for the vial stopper + one for the injection site each day.: 16 weeks: 224 swabs → recommend 3 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily regimen.

Goal: Educational exploration of a p53‑derived peptide studied preclinically for selective cancer‑cell membrane disruption[1][2]. Open source
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 100–500 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 30 mg vial (10 mg/mL) for simplified unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

Start: 100 mcg daily for 1–2 weeks; increase by ~100 mcg every 2 weeks as tolerated.
Target: 300–500 mcg daily by Weeks 5–16.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality[5].

Lyophilized: Store at −20 °C (−4 °F) or colder (−80 °C / −112 °F ideal) in dry, dark conditions; short‑term refrigeration at 2–8 °C (35.6–46.4 °F) is acceptable for days to weeks.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within approximately 30 days and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

Use new sterile insulin syringes; dispose in a sharps container.
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
Regulatory Warning: PNC-27 has no FDA approval and no established human safety data[3]. This information is strictly educational. Open source

How This Works

PNC-27 is a chimeric peptide consisting of a segment derived from the p53 tumor suppressor protein (residues 12–26) fused to a membrane‑penetrating leader sequence[1]. Preclinical studies indicate that PNC-27 selectively binds to HDM‑2 expressed on the surface of cancer cells, inducing membrane destabilization and necrotic cell death while sparing normal cells[2][6]. Research in mouse tumor models has demonstrated inhibition of cancer cell growth via intraperitoneal administration[4]. No human clinical studies have been conducted, and all dosing protocols remain theoretical extrapolations from preclinical work.

Lifestyle Factors

General supportive strategies (not specific to PNC-27).

Maintain a balanced, nutrient‑dense diet to support overall metabolic function.
Prioritize adequate sleep and stress management for immune and recovery support.
Consult qualified healthcare professionals before any experimental peptide use.

Potential Benefits & Side Effects

Observations from preclinical literature only—no human data available.

Preclinical studies suggest selective cytotoxicity toward cancer cells expressing abnormal p53/HDM‑2 while sparing normal cells[2][6]. Open source
Mechanism involves direct membrane lysis rather than apoptosis in affected cells[7]. Open source
No human safety data: The FDA explicitly warns that PNC-27 safety and efficacy have not been established[3]. Open source
Possible injection‑site reactions (redness, irritation) may occur with subcutaneous administration.

Injection Technique

General subcutaneous guidance from clinical best‑practice resources[8][9].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[8]. Open source
Do not aspirate for subcutaneous injections; inject slowly and steadily[9]. Open source
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[10]. Open source

Recommended Source

We recommend Prime Lab Peptides for high‑purity PNC-27 (30 mg).

High‑purity, third‑party‑tested lots with batch COAs.
Consistent, ISO‑aligned handling and documentation.
Reliable fulfillment to maintain cold‑chain integrity.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References